30 June 2017
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
Appointment of Paul Stockdale as Chief Financial Officer
Oxford BioDynamics Plc ("OBD" or the "Company"), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, today announces the appointment of Paul Stockdale as Chief Financial Officer (CFO). Paul is expected to join the Company by 15 September 2017 and will be appointed to the Board of Directors in due course.
Paul succeeds Katie Long who is returning to her role within Tessera Investment Management Limited ("Tessera"), having established and led OBD's finance function over the previous nine months and during the Company's IPO. Katie will step down from the Board on 30 June 2017 and will support OBD on an interim basis in the transitional period.
Paul joins the Company from e-Therapeutics plc (AIM:ETX), where he has held the position of Financial Controller since January 2012. During this time he has worked closely with the CFO and has been responsible for internal and external financial reporting, and developing and maintaining financial and operational systems. Paul is a Chartered Accountant and was a Senior Manager at Deloitte, where he worked from 1996 until 2004. Following this, he worked in finance and operations management in the charitable and automotive sectors. He read Natural Sciences at St John's College, University of Cambridge.
Christian Hoyer Millar, Chief Executive Officer of Oxford BioDynamics, said:
"We are delighted to welcome Paul Stockdale to the Company. Paul's extensive financial management experience, including his recent experience in another public company focused on drug discovery, will be important as OBD strides towards becoming the industry standard for epigenetic biomarker discovery.
The Board would like to take this opportunity to thank Katie for her invaluable contribution during this pivotal time for OBD. We wish her well on her return to Tessera."
The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Paul Leslie Stockdale, aged 42 years, has been a director of the following companies during the five years preceding the date of this announcement:
Current directorships |
Past Directorships |
None |
PL & JE Services Limited |
The Company confirms that there is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.
For further details contact:
Oxford BioDynamics Plc |
|
+44 (0)1865 518910 |
Christian Hoyer Millar, CEO |
|
|
Katie Long, CFO |
|
|
|
|
|
Stifel Nicolaus Europe Limited |
|
+44 (0)20 7710 7600 |
Nominated Advisor and Broker |
|
|
David Arch |
|
|
Jonathan Senior |
|
|
Peter Lees |
|
|
Ben Maddison |
|
|
|
|
|
Shore Capital |
|
+44 (0)20 7408 4090 |
Joint Broker |
|
|
Bidhi Bhoma |
|
|
Edward Mansfield |
|
|
|
|
|
FTI Consulting |
|
+44 (0)20 3727 1000 |
Financial Public Relations Advisor |
|
|
Julia Phillips |
|
|
Brett Pollard |
|
|
Natalie Garland-Collins |
|
|
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a revenue‐generating biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.
The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.
In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.
Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.
